The renin-angiotensin-aldosterone system and calcium-regulatory hormones

Journal of Human Hypertension

Volumn 29, Issue 9, 2015, Pages 515-521

  Vaidya, A ^a   Brown, J M ^a   Williams, J S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; CALCIUM; PARATHYROID HORMONE; RENIN; VITAMIN D; PTH PROTEIN, HUMAN;

ALDOSTERONE RELEASE; CALCIUM ABSORPTION; CALCIUM BLOOD LEVEL; CALCIUM HOMEOSTASIS; ENZYME ACTIVATION; HUMAN; NONHUMAN; PLASMA RENIN ACTIVITY; PRIMARY HYPERALDOSTERONISM; PROTEIN EXPRESSION; PROTEIN INTERACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENIN RELEASE; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; ELECTROLYTE BALANCE; METABOLISM; PATHOPHYSIOLOGY;

ALDOSTERONE; ANIMALS; BLOOD PRESSURE; CALCIUM; CARDIOVASCULAR DISEASES; HUMANS; PARATHYROID HORMONE; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION; VITAMIN D; WATER-ELECTROLYTE BALANCE;

EID: 84939257304     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2014.125     Document Type: Review

References (114)

1. Laragh JH, Sealey JE. The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasoconstriction to longterm blood pressure. Am J Hypertens 2011; 24(11): 1164-1180.
2. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341 (10): 709-717.
3. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342(3): 145-153.
4. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357(3): 266-281.
5. Bilezikian JP, Brandi ML, Rubin M, Silverberg SJ. Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical features. J Intern Med 2005; 257(1): 6-17.
6. Silverberg SJ. Vitamin D deficiency and primary hyperparathyroidism. J Bone Miner Res 2007; 22(Suppl 2): V100-V104.
7. van Ballegooijen AJ, Reinders I, Visser M, Dekker JM, Nijpels G, Stehouwer CD et al. Serum parathyroid hormone in relation to all-cause and cardiovascular mortality: the Hoorn study. J Clin Endocrinol Metab 2013; 98: E638-E645.
8. Pilz S, Tomaschitz A, Drechsler C, Ritz E, Boehm BO, Grammer TB et al. Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. Eur Heart J 2010; 31(13): 1591-1598.
9. Forman JP, Scott JB, Ng K, Drake BF, Suarez EG, Hayden DL et al. Effect of vitamin D supplementation on blood pressure in blacks. Hypertension 2013; 61(4): 779-785.
10. Sempos CT, Durazo-Arvizu RA, Dawson-Hughes B, Yetley EA, Looker AC, Schleicher RL et al. Is there a reverse J-shaped association between 25-hydroxyvitamin D and all-cause mortality? Results from the U.S. nationally representative NHANES. J Clin Endocrinol Metab 2013; 98(7): 3001-3009.
11. Bjelakovic G, Gluud LL, Nikolova D, Whitfield K, Wetterslev J, Simonetti RG et al. Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev 2014; 1: CD007470.
12. Durup D, Jorgensen HL, Christensen J, Schwarz P, Heegaard AM, Lind B. A reverse J-shaped association of all-cause mortality with serum 25-hydroxyvitamin D in general practice: the CopD study. J Clin Endocrinol Metab 2012; 97(8): 2644-2652.
13. Vaidya A, Forman JP. Vitamin D and hypertension: current evidence and future directions. Hypertension 2010; 56(5): 774-779.
14. Vaidya A, Forman JP. The future of vitamin D in vascular disease: reviewing the role of vitamin D in hypertension and kidney disease. Curr Hypertens Rep 2012; 14(2): 111-119.
15. Vaidya A, Williams JS. The relationship between vitamin D and the renin-angiotensin system in the pathophysiology of hypertension, kidney disease, and diabetes. Metabolism 2012; 61(4): 450-458.
16. Foley RN, Collins AJ, Ishani A, Kalra PA. Calcium-phosphate levels and cardiovascular disease in community-dwelling adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 2008; 156(3): 556-563.
17. Hassan M, Qureshi W, Sroujieh LS, Albashaireh D, BouMalham S, Liroff M et al. Interplay of parathyroid hormone and aldosterone antagonist in prevention of heart failure hospitalizations in chronic kidney disease. J Renin-Angiotensin- Aldosterone Syst 2014; 15(3): 278-285.
18. Jorde R, Sundsfjord J, Fitzgerald P, Bonaa KH. Serum calcium and cardiovascular risk factors and diseases: the Tromso Study. Hypertension 1999; 34(3): 484-490.
19. Kamycheva E, Sundsfjord J, Jorde R. Serum parathyroid hormone levels predict coronary heart disease: the Tromso Study. Eur J Cardiovasc Prev Rehabil 2004; 11 (1): 69-74.
20. Larsson TE, Olauson H, Hagstrom E, Ingelsson E, Arnlov J, Lind L et al. Conjoint effects of serum calcium and phosphate on risk of total, cardiovascular, and noncardiovascular mortality in the community. Arterioscler Thromb Vasc Biol 2010; 30(2): 333-339.
21. Lind L, Skarfors E, Berglund L, Lithell H, Ljunghall S. Serum calcium: a new, independent, prospective risk factor for myocardial infarction in middle-aged men followed for 18 years. J Clin Epidemiol 1997; 50(8): 967-973.
22. Bianchetti MG, Beretta-Piccoli C, Weidmann P, Link L, Boehringer K, Ferrier C et al. Calcium and blood pressure regulation in normal and hypertensive subjects. Hypertension 1983; 5(4, Part 2): Ii57-Ii65.
23. Gennari C, Nami R, Bianchini C, Aversa AM. Blood pressure effects of acute hypercalcemia in normal subjects and thyroparathyroidectomized patients. Miner Electrolyte Metab 1985; 11(6): 369-373.
24. Kamycheva E, Jorde R, Haug E, Sager G, Sundsfjord J. Effects of acute hypercalcaemia on blood pressure in subjects with and without parathyroid hormone secretion. Acta Physiol Scand 2005; 184(2): 113-119.
25. Marone C, Beretta-Piccoli C, Weidmann P. Acute hypercalcemic hypertension in man: role of hemodynamics, catecholamines, and renin. Kidney Int 1981; 20(1): 92-96.
26. Berridge MJ, Lipp P, Bootman MD. The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol 2000; 1(1): 11-21.
27. Atchison DK, Beierwaltes WH. The influence of extracellular and intracellular calcium on the secretion of renin. Pflugers Archiv 2013; 465(1): 59-69.
28. Friis UG, Madsen K, Stubbe J, Hansen PB, Svenningsen P, Bie P et al. Regulation of renin secretion by renal juxtaglomerular cells. Pflugers Archiv 2013; 465(1): 25-37.
29. Kotchen TA, Guthrie GP Jr.. Effects of calcium on renin and aldosterone. Am J Cardiol 1988; 62(11): 41g-46gg.
30. Macgriff S, Woo RE, Ortiz-Capisano MC, Atchison DK, Beierwaltes WH. Recruited renin-containing renal microvascular cells demonstrate the calcium paradox regulatory phenotype. Integr Blood Pressure Control 2014; 7: 9-17.
31. Park CS, Malvin RL. Calcium in the control of renin release. Am J Physiol 1978; 235 (1): F22-F25.
32. Facemire CS, Nguyen M, Jania L, Beierwaltes WH, Kim HS, Koller BH et al. A major role for the EP4 receptor in regulation of renin. Am J Physiol Renal Physiol 2011; 301(5): F1035-F1041.
33. Friis UG, Jensen BL, Sethi S, Andreasen D, Hansen PB, Skott O. Control of renin secretion from rat juxtaglomerular cells by cAMP-specific phosphodiesterases. Circ Res 2002; 90(9): 996-1003.
34. Friis UG, Stubbe J, Uhrenholt TR, Svenningsen P, Nusing RM, Skott O et al. Prostaglandin E2 EP2 and EP4 receptor activation mediates cAMP-dependent hyperpolarization and exocytosis of renin in juxtaglomerular cells. Am J Physiol Renal Physiol 2005; 289(5): F989-F997.
35. Kurtz A, Pfeilschifter J, Hutter A, Buhrle C, Nobiling R, Taugner R et al. Role of protein kinase C in inhibition of renin release caused by vasoconstrictors. Am J Physiol 1986; 250(4, Part 1): C563-C571.
36. Ortiz-Capisano MC, Liao TD, Ortiz PA, Beierwaltes WH. Calcium-dependent phosphodiesterase 1C inhibits renin release from isolated juxtaglomerular cells. Am J Physiol Regul Integr Comp Physiol 2009; 297(5): R1469-R1476.
37. Ortiz-Capisano MC, Ortiz PA, Harding P, Garvin JL, Beierwaltes WH. Adenylyl cyclase isoform v mediates renin release from juxtaglomerular cells. Hypertension 2007; 49(3): 618-624.
38. Ortiz-Capisano MC, Ortiz PA, Harding P, Garvin JL, Beierwaltes WH. Decreased intracellular calcium stimulates renin release via calcium-inhibitable adenylyl cyclase. Hypertension 2007; 49(1): 162-169.
39. Ortiz-Capisano MC, Reddy M, Mendez M, Garvin JL, Beierwaltes WH. Juxtaglomerular cell CaSR stimulation decreases renin release via activation of the PLC/IP(3) pathway and the ryanodine receptor. Am J Physiol Renal Physiol 2013; 304(3): F248-F256.
40. Atchison DK, Harding P, Beierwaltes WH. Hypercalcemia reduces plasma renin via parathyroid hormone, renal interstitial calcium, and the calcium-sensing receptor. Hypertension 2011; 58(4): 604-610.
41. Atchison DK, Ortiz-Capisano MC, Beierwaltes WH. Acute activation of the calcium-sensing receptor inhibits plasma renin activity in vivo. Am J Physiol Regul Integr Compar Physiol 2010; 299(4): R1020-R1026.
42. Ortiz-Capisano MC, Ortiz PA, Garvin JL, Harding P, Beierwaltes WH. Expression and function of the calcium-sensing receptor in juxtaglomerular cells. Hypertension 2007; 50(4): 737-743.
43. Friis UG, Jorgensen F, Andreasen D, Jensen BL, Skott O. Membrane potential and cation channels in rat juxtaglomerular cells. Acta Physiol Scand 2004; 181(4): 391-396.
44. Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O et al. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 1993; 366(6455): 575-580.
45. Brown EM, MacLeod RJ. Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev 2001; 81(1): 239-297.
46. Riccardi D, Park J, Lee WS, Gamba G, Brown EM, Hebert SC. Cloning and functional expression of a rat kidney extracellular calcium/polyvalent cation-sensing receptor. Proc Natl Acad Sci USA 1995; 92(1): 131-135.
47. Isaac R, Raymond JP, Rainfray M, Ardaillou R. Effects of an acute calcium load on plasma ACTH, cortisol, aldosterone and renin activity in man. Acta Endocrinol 1984; 105(2): 251-257.
48. Richards AM, Espiner EA, Nicholls MG, Ikram H, Hamilton EJ, Maslowski AH. Hormone, calcium and blood pressure relationships in primary hyperparathyroidism. J Hypertens 1988; 6(9): 747-752.
49. Valvo E, Bedogna V, Gammaro L, Casagrande P, Ortalda V, Maschio G. Systemic hemodynamic pattern in primary hyperparathyroidism and its changes after parathyroidectomy. Miner Electrolyte Metab 1991; 17(3): 147-152.
50. Watanabe S, Fukumoto S, Chang H, Takeuchi Y, Hasegawa Y, Okazaki R et al. Association between activating mutations of calcium-sensing receptor and Bartter's syndrome. Lancet 2002; 360(9334): 692-694.
51. Tomaschitz A, Ritz E, Pieske B, Rus-Machan J, Kienreich K, Verheyen N et al. Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease. Metabolism 2014; 63(1): 20-31.
52. Brown JM, Vaidya A. Interactions between adrenal-regulatory and calciumregulatory hormones in human health. Curr Opin Endocrinol Diabetes Obes 2014; 21(3): 193-201.
53. Resnick LM, Laragh JH. Calcium metabolism and parathyroid function in primary aldosteronism. Am J Med 1985; 78(3): 385-390.
54. Rossi E, Sani C, Perazzoli F, Casoli MC, Negro A, Dotti C. Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas. Am J Hypertens 1995; 8(9): 884-893.
55. Pilz S, Kienreich K, Drechsler C, Ritz E, Fahrleitner-Pammer A, Gaksch M et al. Hyperparathyroidism in patients with primary aldosteronism: cross-sectional and interventional data from the GECOH study. J Clin Endocrinol Metab 2012; 97(1): E75-E79.
56. Maniero C, Fassina A, Seccia TM, Toniato A, Iacobone M, Plebani M et al. Mild hyperparathyroidism: a novel surgically correctable feature of primary aldosteronism. J Hypertens 2012; 30(2): 390-395.
57. Rossi GP, Ragazzo F, Seccia TM, Maniero C, Barisa M, Calo LA et al. Hyperparathyroidism can be useful in the identification of primary aldosteronism due to aldosterone-producing adenoma. Hypertension 2012; 60(2): 431-436.
58. Chhokar VS, Sun Y, Bhattacharya SK, Ahokas RA, Myers LK, Xing Z et al. Loss of bone minerals and strength in rats with aldosteronism. Am J Physiol Heart Circ Physiol 2004; 287(5): H2023-H2026.
59. Runyan AL, Chhokar VS, Sun Y, Bhattacharya SK, Runyan JW, Weber KT. Bone loss in rats with aldosteronism. Am J Med Sci 2005; 330(1): 1-7.
60. Salcuni AS, Palmieri S, Carnevale V, Morelli V, Battista C, Guarnieri V et al. Bone involvement in aldosteronism. J Bone Miner Res 2012; 27(10): 2217-2222.
61. Ceccoli L, Ronconi V, Giovannini L, Marcheggiani M, Turchi F, Boscaro M et al. Bone health and aldosterone excess. Osteoporos Int 2013; 24(11): 2801-2807.
62. Petramala L, Zinnamosca L, Settevendemmie A, Marinelli C, Nardi M, Concistre A et al. Bone and mineral metabolism in patients with primary aldosteronism. Int J Endocrinol 2014; 2014: 836529.
63. Beavan S, Horner A, Bord S, Ireland D, Compston J. Colocalization of glucocorticoid and mineralocorticoid receptors in human bone. J Bone Miner Res 2001; 16(8): 1496-1504.
64. Carbone LD, Cross JD, Raza SH, Bush AJ, Sepanski RJ, Dhawan S et al. Fracture risk in men with congestive heart failure risk reduction with spironolactone. J Am Coll Cardiol 2008; 52(2): 135-138.
65. Koiwa F, Komukai D, Hirose M, Yoshimura A, Ando R, Sakaguchi T et al. Influence of renin-angiotensin system on serum parathyroid hormone levels in uremic patients. Clin Exp Nephrol 2012; 16(1): 130-135.
66. Maniero C, Fassina A, Guzzardo V, Lenzini L, Amadori G, Pelizzo MR et al. Primary hyperparathyroidism with concurrent primary aldosteronism. Hypertension 2011; 58(3): 341-346.
67. Brown JM, Williams JS, Luther JM, Garg R, Garza AE, Pojoga LH et al. Human interventions to characterize novel relationships between the renin-angiotensin- aldosterone system and parathyroid hormone. Hypertension 2014; 63(2): 273-280.
68. Chau K, Holmes D, Melck A, Chan-Yan C. Secondary hypertension due to concomitant aldosterone-producing adenoma and parathyroid adenoma. Am J Hypertens (e-pub ahead of print 20 June 2014).
69. Rastegar A, Agus Z, Connor TB, Goldberg M. Renal handling of calcium and phosphate during mineralocorticoid 'escape' in man. Kidney Int 1972; 2(5): 279-286.
70. Rossi E, Perazzoli F, Negro A, Sani C, Davoli S, Dotti C et al. Acute effects of intravenous sodium chloride load on calcium metabolism and on parathyroid function in patients with primary aldosteronism compared with subjects with essential hypertension. Am J Hypertens 1998; 11(1, Part 1): 8-13.
71. Grant FD, Mandel SJ, Brown EM, Williams GH, Seely EW. Interrelationships between the renin-angiotensin-aldosterone and calcium homeostatic systems. J Clin Endocrinol Metab 1992; 75(4): 988-992.
72. Vaidya A, Sun B, Larson C, Forman JP, Williams JS. Vitamin D3 therapy corrects the tissue sensitivity to angiotensin II akin to the action of a converting enzyme inhibitor in obese hypertensives: An Interventional Study. J Clin Endocrinol Metab 2012; 97(7): 2456-2465.
73. Fischer E, Hannemann A, Rettig R, Lieb W, Nauck M, Pallauf A et al. A High aldosterone-to-renin ratio is associated with high serum parathyroid hormone concentrations in the general population. J Clin Endocrinol Metab 2014; 99(3): 965-971.
74. Brown JM, de Boer IH, Robinson-Cohen C, Kestenbaum B, Siscovick D, Allison MA et al. Aldosterone, parathyroid hormone, and the use of renin-angiotensinaldosterone system inhibitors: the multi-ethnic study of atherosclerosis. J Clin Endocrinol Metab (e-pub ahead of print 20 November 2014).
75. van Ballegooijen AJ, Kestenbaum B, Sachs MC, de Boer IH, Siscovick DS, Hoofnagle AN et al. Association of 25-hydroxyvitamin D and parathyroid hormone with incident hypertension: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 2014; 63(12): 1214-1222.
76. van Ballegooijen AJ, Visser M, Kestenbaum B, Siscovick DS, de Boer IH, Gottdiener JS et al. Relation of vitamin D and parathyroid hormone to cardiac biomarkers and to left ventricular mass (from the Cardiovascular Health Study). Am J Cardiol 2013; 111(3): 418-424.
77. Tomaschitz A, Pilz S. Interplay between sodium and calcium regulatory hormones: a clinically relevant research field. Hypertension 2014; 63(2): 212-214.
78. Isales CM, Barrett PQ, Brines M, Bollag W, Rasmussen H. Parathyroid hormone modulates angiotensin II-induced aldosterone secretion from the adrenal glomerulosa cell. Endocrinology 1991; 129(1): 489-495.
79. Mazzocchi G, Aragona F, Malendowicz LK, Nussdorfer GG. PTH and PTH-related peptide enhance steroid secretion from human adrenocortical cells. Am J Physiol Endocrinol Metab 2001; 280(2): E209-E213.
80. Hulter HN, Melby JC, Peterson JC, Cooke CR. Chronic continuous PTH infusion results in hypertension in normal subjects. J Clin Hypertens 1986; 2(4): 360-370.
81. Saussine C, Judes C, Massfelder T, Musso MJ, Simeoni U, Hannedouche T et al. Stimulatory action of parathyroid hormone on renin secretion in vitro: a study using isolated rat kidney, isolated rabbit glomeruli and superfused dispersed rat juxtaglomerular cells. Clin Sci 1993; 84(1): 11-19.
82. Helwig JJ, Musso MJ, Judes C, Nickols GA. Parathyroid hormone and calcium: interactions in the control of renin secretion in the isolated, nonfiltering rat kidney. Endocrinology 1991; 129(3): 1233-1242.
83. Fallo F, Rocco S, Pagotto U, Zangari M, Luisetto G, Mantero F. Aldosterone and pressor responses to angiotensin II in primary hyperparathyroidism. J Hypertens Suppl 1989; 7(6): S192-S193.
84. Barkan A, Marilus R, Winkelsberg G, Yeshurun D, Blum I. Primary hyperparathyroidism: possible cause of primary hyperaldosteronism in a 60-yearold woman. J Clin Endocrinol Metab 1980; 51(1): 144-147.
85. Bernini G, Moretti A, Lonzi S, Bendinelli C, Miccoli P, Salvetti A. Renin-angiotensin- aldosterone system in primary hyperparathyroidism before and after surgery. Metabolism 1999; 48(3): 298-300.
86. Tomaschitz A, Pilz S, Ritz E, Grammer T, Drechsler C, Boehm BO et al. Independent association between 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D and the renin-angiotensin system The Ludwigshafen Risk and Cardiovascular Health (LURIC) Study. Clin Chim Acta 2010; 411(17-18): 1354-1360.
87. Li YC. Vitamin D regulation of the renin-angiotensin system. J Cell Biochem 2003; 88(2): 327-331.
88. Li YC. Inhibition of renin: an updated review of the development of renin inhibitors. Curr Opin Invest Drugs 2007; 8(9): 750-757.
89. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110(2): 229-238.
90. Yuan W, Pan W, Kong J, Zheng W, Szeto FL, Wong KE et al. 1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem 2007; 282(41): 29821-29830.
91. Zhang Y, Deb DK, Kong J, Ning G, Wang Y, Li G et al. Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist. Am J Physiol Renal Physiol 2009; 297(3): F791-F801.
92. Zhang Y, Kong J, Deb DK, Chang A, Li YC. Vitamin D receptor attenuates renal fibrosis by suppressing the renin-angiotensin system. J Am Soc Nephrol 2010; 21 (6): 966-973.
93. Freundlich M, Li YC, Quiroz Y, Bravo Y, Seeherunvong W, Faul C et al. Paricalcitol downregulates myocardial renin-angiotensin and fibroblast growth factor expression and attenuates cardiac hypertrophy in uremic rats. Am J Hypertens. 2014; 27(5): 720-726.
94. Forman JP, Williams JS, Fisher ND. Plasma 25-hydroxyvitamin D and regulation of the renin-angiotensin system in humans. Hypertension 2010; 55(5): 1283-1288.
95. Vaidya A, Forman JP, Seely EW, Williams JS. 25-Hydroxyvitamin D is Associated with plasma renin activity and the pressor response to dietary sodium intake in caucasians. J Renin-Angiotensin-Aldosterone Syst 2011; 12(3): 311-319.
96. Carrara D, Bernini M, Bacca A, Rugani I, Duranti E, Virdis A et al. Cholecalciferol administration blunts the systemic renin-angiotensin system in essential hypertensives with hypovitaminosis D. J Renin-Angiotensin-Aldosterone Syst 2014; 15(1): 82-87.
97. Larsen T, Mose FH, Bech JN, Pedersen EB. Effect of paricalcitol on renin and albuminuria in non-diabetic stage III-IV chronic kidney disease: a randomized placebo-controlled trial. BMC Nephrol 2013; 14: 163.
98. de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010; 376(9752): 1543-1551.
99. Joergensen C, Tarnow L, Goetze JP, Rossing P. Vitamin D analogue therapy, cardiovascular risk and kidney function in people with Type 1 diabetes mellitus and diabetic nephropathy: a randomized trial. Diabetes Med (e-pub ahead of print 11 October 2014; doi:10.1111/dme.12606).
100. Scragg R, Slow S, Stewart AW, Jennings LC, Chambers ST, Priest PC et al. Long-term high-dose vitamin D3 supplementation and blood pressure in healthy adults: A Randomized Controlled Trial. Hypertension 2014; 64(4): 725-730.
101. Witham MD, Price RJ, Struthers AD, Donnan PT, Messow CM, Ford I et al. Cholecalciferol treatment to reduce blood pressure in older patients with isolated systolic hypertension: the VitDISH randomized controlled trial. JAMA Intern Med 2013; 173(18): 1672-1679.
102. Arora P, Song Y, Dusek J, Plotnikoff G, Sabatine M, Cheng S et al. Vitamin D therapy in individuals with pre-hypertension or hypertension: The DAYLIGHT Trial. Circulation (e-pub ahead of print 30 October 2014).
103. Manson JE, Bassuk SS, Lee IM, Cook NR, Albert MA, Gordon D et al. The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials 2012; 33(1): 159-171.
104. Powe CE, Karumanchi SA, Thadhani R. Vitamin D-binding protein and vitamin D in blacks and whites. N Engl J Med 2014; 370(9): 880-881.
105. Hollis BW, Bikle DD. Vitamin D-binding protein and vitamin D in blacks and whites. N Engl J Med 2014; 370(9): 879-880.
106. Park HY, Kim JH, Bae S, Choi YY, Park JY, Hong YC. Interaction effect of serum 25-hydroxyvitamin D levels and CYP1A1, CYP1B1 polymorphisms on blood pressure in an elderly population. J Hypertens 2015; 33(1): 69-76.
107. Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, Berry D et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 2010; 376(9736): 180-188.
108. Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA, Van Leeuwen JP. Genetics and biology of vitamin D receptor polymorphisms. Gene 2004; 338(2): 143-156.
109. McGrath JJ, Saha S, Burne TH, Eyles DW. A systematic review of the association between common single nucleotide polymorphisms and 25-hydroxyvitamin D concentrations. J Steroid Biochem Mol Biol 2010; 121(1-2): 471-477.
110. Wang L, Ma J, Manson JE, Buring JE, Gaziano JM, Sesso HD. A prospective study of plasma vitamin D metabolites, vitamin D receptor gene polymorphisms, and risk of hypertension in men. Eur J Nutr 2013; 52(7): 1771-1779.
111. Swapna N, Vamsi UM, Usha G, Padma T. Risk conferred by FokI polymorphism of vitamin D receptor (VDR) gene for essential hypertension. Indian J Hum Genet 2011; 17(3): 201-206.
112. Solak Y, Covic A, Kanbay M. What do we know and do not know about vitamin D?: A causal association between vitamin D receptor genetic polymorphism and hypertension. J Clin Hypertens (Greenwich) 2014; 16(9): 627-628.
113. Vaidya A, Sun B, Forman JP, Hopkins PN, Brown NJ, Kolatkar NS et al. The vitamin D receptor gene polymorphism Fok1 is associated with plasma renin activity in caucasians. Clin Endocrinol (Oxf) 2011; 74(6): 783-790.
114. Levin GP, Robinson-Cohen C, de Boer IH, Houston DK, Lohman K, Liu Y et al. Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes. JAMA 2012; 308(18): 1898-1905.